509150-43-0

Basic information

• Product Name: IMidodicarbonic acid, 2-(5-nitro-2-pyridinyl)-, 1,3-bis(1,1-diMethylethyl) ester
• Synonyms: IMidodicarbonic acid, 2-(5-nitro-2-pyridinyl)-, 1,3-bis(1,1-diMethylethyl) ester;N,N-Bis-Boc-5-Nitro-pyridin-2-ylamine
• CAS NO: 509150-43-0
• Molecular Formula: C15H21N3O6
• Molecular Weight: 339.34374
• Mol File: 509150-43-0.mol

Chemical Properties

• Boiling Point: 436.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.249±0.06 g/cm3(Predicted)
• PKA: -2.68±0.10(Predicted)
• CAS DataBase Reference: IMidodicarbonic acid, 2-(5-nitro-2-pyridinyl)-, 1,3-bis(1,1-diMethylethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: IMidodicarbonic acid, 2-(5-nitro-2-pyridinyl)-, 1,3-bis(1,1-diMethylethyl) ester(509150-43-0)
• EPA Substance Registry System: IMidodicarbonic acid, 2-(5-nitro-2-pyridinyl)-, 1,3-bis(1,1-diMethylethyl) ester(509150-43-0)

Safety Data

• Hazardous Substances Data: 509150-43-0(Hazardous Substances Data)

Upstream product

• 4214-76-0 5-nitro-pyridin-2-ylamine 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

HETEROARYLAMINOISOQUINOLINES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF

The application is directed to compounds of formula (IA) : and specifically compounds of formula (I) and their salts and solvates, wherein R1, R11, R12, R13, R4, R5, n, A1, A2, and A3 are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of β-galactosidase, specially galactosidase beta-1 or GLB1, including GM1 gangliosidoses and Morquio syndrome, type B.

Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 1: SAR of modifications to the central aryl core

This Letter describes the lead optimization of the VU0486321 series of mGlu1 positive allosteric modulators (PAMs). While first generation PAMs from Roche were reported in the late 1990s, little effort has focused on the development of mGlu1 PAMs since. New genetic data linking loss-of-function mutant mGlu1 receptors to schizophrenia, bipolar disorder and other neuropsychiatric disorders has rekindled interest in the target, but the ideal in vivo probe, for example, with good PK, brain penetration and low plasma protein binding, for robust target validation has been lacking. Here we describe the first modifications to the central aryl core of the VU0486321 series, where robust SAR was noted. Moreover, structural variants were identified that imparted selectivity (up to >793-fold) versus mGlu4.

USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES

The present invention relates to the use of 2,5-diamidoindole derivatives for the preparation of medicaments for treating urological disorders in humans and/or animals.RCK 41-Foreign Countries